Leonard D. Schaeffer Center for Health Policy and Economics postdoctoral research fellow Meng Li discussed real option value during a presentation at the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) annual meeting.
Li during her presentation, “Real Option Value for Drugs — Is it Really an Option?”, said real option value is key in the current environment due to the rapid pace of technological innovation, according to a report by the American Journal of Managed Care (AJMC).
